Specialty Pharmacy

Specialty Therapies Drive Significant Increase in US Drug Spending in 2014

Spending on specialty drugs took a record rise in the US in 2014, largely due to new expensive, yet effective, hepatitis C drugs, according to new data released today in the 2014 Express Scripts Drug Trend Report. According to the pharmacy benefit manager’s (PBM) report, new hepatitis C drugs’ high …

Read More »

The Specialty Pharma Education Center (SPEC) Offers Accredited Education Free of Charge

TAMPA, FL, March 9, 2015 — The Specialty Pharma Education Center (SPEC), a global leader in specialty pharmacy education, announced that it no longer requires users to be members of the National Association of Specialty Pharmacy (NASP) to access the education center. The move paves the way for greater participation …

Read More »

FDA Clears First-of-Kind Device to Treat Patients with Dialysis-Related Amyloidosis

US health regulators cleared use of a first-of-its-kind device to treat dialysis-related amyloidosis (DRA). The US Food and Drug Administration (FDA) authorized use of Lixelle Beta 2-microglobulin Apheresis Column under its pathway for medical devices that treat rare conditions. The device is used to treat DRA, a chronic, progressive condition …

Read More »

FDA Approves Astellas’ Cresemba for Rare but Serious Fungal Infections

The US Food and Drug Administration (FDA) has approved Astellas’ new antifungal drug to treat two rare, often fatal invasive fungal infections. The agency approved Astellas’ New Drug Application (NDA) for the use of Cresemba (isavuconazonium sulfate), the prodrug for isavuconazole, for patients 18 years of age and older in …

Read More »

Targacept to Merge with Catalyst Biosciences

Winston-Salem-based Targacept, Inc. has agreed to merge with California-based Catalyst Biosciences Inc., creating a protease-based hemostasis and anti-complement company. The companies said that they entered into a definitive agreement to merge the two companies, which will be named Catalyst Biosciences, Inc. The combined entity is expected to create a financially …

Read More »

CTI BioPharma and Baxter’s Myelofibrosis Drug Meets Primary Endpoint in Late-Stage Trial

Baxter International and CTI BioPharma Corp. announced that its experimental blood cancer drug met its primary endpoint in a late-stage study. The companies announced top-line results for the primary endpoint from PERSIST-1, a Phase III registration clinical trial evaluating pacritinib, an oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients …

Read More »

FDA Approves Sandoz Zarxio as First Biosimilar in the US Market

Sandoz, a Novartis company, is the first company to receive approval of a biosimilar in the US through the new biosimilars pathway. The US Food and Drug Administration (FDA) approved Sandoz’s Zarxio (filgrastim-sndz) for all indications included in the label of the reference product, Neupogen. Amgen’s Neupogen (filgrastim) was originally …

Read More »

Specialty Pharma Journal Launches its Rebranded Logo and Website

Specialty Pharma Journal (SPJ) today announced the launch of its new name, Specialty Precision & Technology Pharma Journal, along with a rebranding initiative which includes a new logo and website. The change reflects the publication’s focus on “precision medicine,” a new healthcare model that uses innovative technologies to tailor treatment …

Read More »

Avella Inks Deal with Sentry Data Systems on 340B Drug Discount Program Efforts

Avella is partnering with technology provider Sentry Data Systems on 340B drug discount program efforts. The pharmacy announced the new partnership with Sentry Data Systems, a leading provider of technology systems that help hospitals and clinics reduce costs, manage compliance and produce better outcomes. The partnership will allow both companies …

Read More »